(RTTNews) – Biotechnology company Novavax Inc. (NVAX) on Tuesday announced an amendment to its existing agreement with the Serum Institute of India Pvt. Ltd. or SIIPL, in which SIIPL will also manufacture the antigenic component of NVX-CoV2373, Novavax’s COVID-19 vaccine candidate.
With this agreement, Novavax is expanding its global production capacity from NVX-CoV2373 to more than two billion doses in line with the year, when all planned capacity has been launched until mid-2021. The agreement expands Novavax’s partnership with the world’s largest vaccine development in accordance with the construction of the global delivery of NVX-CoV2373.
NVX-CoV2373 is a solid prefusion protein made with Novavax’s generation of recombinant protein nanoparticles and includes Novavax’s patented Matrix-M adjuvant.
Novavax said it will continue to work with normal urgency to expand the vaccine, lately in Phase 2 clinical trials, and plans to begin Phase 3 efficacy trials internationally in the coming weeks.
The Novavax Matrix-M additive is recently manufactured at Novavax AB in Uppsala, Sweden, as well as other spouse production sites in the United States and Denmark.